Toft Group Completes Executive Search for Zenith Epigenetics, Ltd. in Calgary, Alberta, Canada

Zenith Epigenetics

Executive search firm Toft Group has placed Dr. Edward van der Horst as Vice President, Discovery Biology & Pre-Clinical Development at Zenith Epigenetics, Ltd., in Calgary, Alberta, Canada. Dr. van der Horst brings 15 years of experience developing monoclonal antibody therapeutics, target discovery, selection and validation. He previously served at Igenica Biotherapeutics as Senior Director of Preclinical Drug Development. Previous, Dr. van der Horst’s contributions and discoveries at OncoMed Pharmaceuticals as a Senior Scientist have led to the development and clinical evaluation of anti-DLL4 and anti-NOTCH2/3 antibodies, the first clinical stage anti-HER3 antibody at U3 Pharma GmbH. Dr. van der Horst earned his MSc in Chemistry from Ludwig-Maximillians University and his PhD in Biochemistry from Max-Planck Institute for Biochemistry, both located in Munich, Germany.

About Zenith Epigenetics, Ltd.

Zenith Capital Corp. is a biotechnology investment company. Zenith Epigenetics Ltd., a wholly-owned subsidiary of Zenith Capital Corp., is a clinical stage biotechnology company focused on the discovery and development of novel therapeutics. Zenith Epigenetics Ltd.’s bromodomain (BET) inhibitors are being advanced in several oncology indications and have the potential to impact multiple additional diseases as well. The lead compound, ZEN-3694, is in clinical development for metastatic Castration Resistant Prostate Cancer (mCRPC).